NOS1 and metabolic disease: The neurovascular mechanisms involved, including an altered astrocytic glutamatergic pathway followed by a loss of the compensatory action of neuronal NOS, represent potential therapeutic targets to be considered alongside preventive care for peripheral metabolic disorders.